Jpmorgan Chase & CO Clovis Oncology, Inc. Transaction History

Jpmorgan Chase & CO

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	BUY	$1.05 - $2.85 $4,770 - $12,947	4,543 Added 80.55%	10,183 $12,000
Q2 2022 Aug 11, 2022	SELL	$0.63 - $2.96 $40,403 - $189,830	-64,132 Reduced 91.92%	5,640 $10,000
Q1 2022 May 11, 2022	BUY	$1.43 - $3.14 $19,180 - $42,116	13,413 Added 23.8%	69,772 $141,000
Q4 2021 Feb 10, 2022	BUY	$2.7 - $4.76 $13,265 - $23,385	4,913 Added 9.55%	56,359 $153,000
Q3 2021 Nov 12, 2021	BUY	$4.06 - $5.8 $208,870 - $298,386	51,446 New	51,446 $229,000

166

Ticker CLVS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 144,480,000
Market Cap $13M
Description
Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. In the U.S., the company offers Rubraca (rucaparib), an oral small molecule inhibitor of poly ADP-ribose polymerase for recurrent epithelial ovarian, fallopian tube, or pr...

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

Stay updated on Jpmorgan Chase & CO with notifications on news.